Inhibikase Therapeutics, Inc.

Historical 13F Holders

Symbol
IKT
CUSIP
45719W205
All holders as of
Q3 2026
Type
Equity
Class
COM NEW
Reported Value, Excluding Options
Total Shares Held, Excluding Options
Total Filers

13D/G Filers

Each filer's latest filing for 45719W205 since 12/18/2024, largest first.

Filer % of Class Filed
RA Capital Management, L.P. 13G/A
9.9% 7/31/2026
Event 7/29/2026
Commodore Capital LP 13G/A
9.9% 5/15/2026
Event 3/31/2026
ADAR1 Capital Management, LLC 13G/A
9.9% 5/15/2026
Event 3/31/2026
Fairmount Funds Management LLC 13G/A
9.9% 2/17/2026
Event 12/31/2025
Sands Capital Life Sciences Pulse Fund II, L.P. 13G/A
9.3% 8/13/2026
Event 6/30/2026
Perceptive Advisors LLC 13G/A
6.9% 8/14/2026
Event 6/30/2026
Trails Edge Capital Partners, LP 13G/A
6.1% 5/15/2026
Event 3/31/2026
BlackRock, Inc. 13G 5.9% 7/28/2026
Event 6/30/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (3)
Armistice Capital, LLC 13G/A
4.99% 2/14/2025
Event 12/31/2024
Nantahala Capital Management, LLC 13G/A
4.3% 8/14/2026
Event 6/30/2026
Point72 Asset Management, L.P. 13G/A
0% 2/14/2025
Event 12/31/2024

13F Holders by Quarter

Period Filers Shares, Excl. Options Value, Excl. Options
2026 Q3 110 127 M $262M
2026 Q2 105 118 M $239M
2026 Q1 104 118 M $198M
2025 Q4 74 106 M $218M
2025 Q3 54 55.0 M $89.0M
2025 Q2 49 54.5 M $106M
2025 Q1 48 51.5 M $113M
2024 Q4 32 50.1 M $163M
2024 Q3 12 860 k $1.12M
2024 Q2 13 836 k $1.02M
2024 Q1 13 206 k $444k
2023 Q4 12 235 k $299k
2023 Q3 14 430 k $598k
2023 Q2 15 747 k $2.69M
2023 Q1 1 82.8 k $54.5k